Cerus (NASDAQ:CERS) Upgraded by Zacks Research to Hold Rating

Key Points

• Zacks upgraded Cerus from "strong sell" to "hold" and other analysts are mixed—BTIG and Wall Street Zen upgraded to "buy" while Weiss remains a "sell"—leaving a consensus Hold rating with an average target of about $4.00.
• Q1 results beat expectations: revenue rose to $59.9M (+~22.6% YoY) and EPS was -$0.01 (ahead of estimates), with positive operating cash flow, but FY2026 guidance of $227–231M sits below consensus and could cap upside.
• Insider selling has been significant—insiders sold ~1.19M shares (~$2.1M) in the last 90 days; insiders own 5.6% of the stock while institutional investors hold about 78.4%, a combination that may affect sentiment.

Cerus (NASDAQ:CERS - Get Free Report) was upgraded by investment analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a research note issued on Thursday,Zacks.com reports.

CERS has been the subject of a number of other reports. Wall Street Zen raised Cerus from a "hold" rating to a "buy" rating in a report on Saturday. BTIG Research raised Cerus from a "neutral" rating to a "buy" rating and set a $4.00 price target for the company in a report on Friday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cerus in a report on Wednesday, March 25th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Cerus in a report on Monday, January 12th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Cerus currently has a consensus rating of "Hold" and an average target price of $4.00.

Cerus Stock Performance

Shares of CERS stock opened at $2.72 on Thursday. The company has a current ratio of 1.73, a quick ratio of 1.17 and a debt-to-equity ratio of 0.62. The firm has a fifty day moving average price of $1.97 and a 200 day moving average price of $1.98. The company has a market cap of $545.01 million, a P/E ratio of -34.00 and a beta of 1.62. Cerus has a 12 month low of $1.15 and a 12 month high of $3.15.

Cerus (NASDAQ:CERS - Get Free Report) last issued its earnings results on Thursday, April 30th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. The firm had revenue of $59.89 million during the quarter, compared to the consensus estimate of $55.68 million. Cerus had a negative net margin of 4.41% and a negative return on equity of 15.63%. Sell-side analysts predict that Cerus will post -0.05 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Vivek K. Jayaraman sold 165,200 shares of the stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $1.66, for a total value of $274,232.00. Following the completion of the sale, the chief operating officer directly owned 1,747,674 shares of the company's stock, valued at approximately $2,901,138.84. This represents a 8.64% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Chrystal Jensen sold 30,845 shares of the stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $2.01, for a total value of $61,998.45. Following the completion of the sale, the insider directly owned 1,059,139 shares of the company's stock, valued at $2,128,869.39. The trade was a 2.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,194,282 shares of company stock valued at $2,106,290 over the last ninety days. Company insiders own 5.60% of the company's stock.

Institutional Investors Weigh In On Cerus

Large investors have recently modified their holdings of the company. Cibc World Markets Corp acquired a new stake in shares of Cerus during the fourth quarter worth about $25,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Cerus during the third quarter worth about $31,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Cerus during the first quarter worth about $32,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Cerus during the first quarter worth about $35,000. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Cerus during the third quarter worth about $35,000. 78.37% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Cerus

Here are the key news stories impacting Cerus this week:

• Positive Sentiment: Q1 results beat expectations: revenue rose ~22.6% YoY to $59.9M and diluted EPS was -$0.01, beating estimates — the top‑line beat and narrower loss are being cited as the primary catalyst lifting the stock. QuiverQuant: Q1 2026 Earnings
• Positive Sentiment: Analyst upgrade: BTIG Research raised CERS from "neutral" to "buy" with a $4.00 price target (material upside to the current level), which can attract momentum buyers and fresh coverage. The Fly / BTIG upgrade
• Positive Sentiment: Improving profitability & cash flow: operating loss narrowed substantially vs. last year, net loss fell sharply, and operating cash flow was positive ($6.2M); these trends reduce near‑term funding pressure. QuiverQuant: financial details
• Neutral Sentiment: Detailed context is available in the earnings call/transcripts for investors who want management color on growth drivers and timing. Seeking Alpha Transcript
• Neutral Sentiment: Small government contract receipts and mixed institutional flows: some large funds added positions while others reduced holdings — signals of both conviction and rotation into/out of the name. QuiverQuant: institutional & contract data
• Negative Sentiment: FY2026 revenue guidance was updated to $227.0M–$231.0M, which sits below consensus (~$233.9M) — the guide shortfall may cap upside if investors focus on FY outlook rather than the quarterly beat. MarketBeat: guidance note
• Negative Sentiment: Significant insider selling over recent months is a red flag for some investors and may weigh on sentiment despite improving results. QuiverQuant: insider trades

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.